Phase 1/2 interim data on moderna's mrna-3927, an investigational mrna therapy for propionic acidemia (pa), presented at the 2023 asgct annual meeting

First clinical trial reporting results of an mrna therapeutic for intracellular protein replacement to date, mrna-3927 has been generally well-tolerated at the doses administered, with encouraging early signs of dose-dependent pharmacology and potential clinical benefits no occurrence of dose-limiting toxicities or study discontinuations due to drug-related treatment-emergent adverse events (teaes) more than 280 doses of mrna-3927 were administered. five patients have more than a year of dosing phase 1/2 trial advances to the dose-expansion phase cambridge, ma / accesswire / may 19, 2023 / moderna,inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, reported on interim data from the phase 1/2 trial of mrna-3927, an investigational mrna therapy for propionic acidemia (pa), presented at the 2023 american society of gene + cell therapy (asgct) annual meeting.
MRNA Ratings Summary
MRNA Quant Ranking